Cite
APA Citation
Kerr, R. S., Love, S., Segelov, E., Johnstone, E., Falcon, B., Hewett, P., Weaver, A., Church, D., Scudder, C., Pearson, S., Julier, P., Pezzella, F., Tomlinson, I., Domingo, E., & Kerr, D. J. (n.d.). adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet oncology, 17(11), 1543–1557. http://access.bl.uk/ark:/81055/vdc_100038840370.0x000033